Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delphi Technologies (DLPH) upgraded to Buy from Neutral at Goldman Sachs with analyst David Tamberrino saying new CEO Rick Dauch's more operationally focused initiatives should drive "idiosyncratic" margin and free cash flow expansion into 2020. 2. Williams-Sonoma (WSM) upgraded to Accumulate from Hold at Gordon Haskett with analyst Chuck Grom saying following the meetings, and based on more upbeat than expected results from peer RH (RH), he has a higher degree of confidence about both the company's near-term results and its long-term options. 3. Concert Pharmaceuticals (CNCE) upgraded to Buy from Neutral at Janney Montgomery Scott with analyst Esther Hong saying CTP-692 broadens Concert 's clinical pipeline. 4. CenterPoint Energy (CNP) upgraded to Buy on valuation at BofA/Merrill with analyst Julien Dumoulin-Smith citing "compelling" valuation. 5. HCP (HCP) upgraded to Outperform from Market Perform at Raymond James with analyst Jonathan Hughes citing relative valuation and size, development contributions visibility, and accelerating same-store NOI growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

IBM (IBM) is nearing a deal to acquire HashiCorp (HCP) for about $35 per share, Ryan Gould and Brody Ford of Bloomberg report, citing people with knowledge of the matter. IBM and HashiCorp could announce the deal as soon as Wednesday, sources told Bloomberg. Shares of HashiCorp are up 9% to $31.81 following the report.

IBM (IBM) is scheduled to report results of its fiscal first quarter after the market close on April 24, with a conference call scheduled for 5:00 pm ET. What to watch... To see the rest of the story go to thefly.com. See Story Here

BTIG downgraded HashiCorp (HCP) to Neutral from Buy without a price target. The analyst sees a balanced risk/reward after the stock's recent run following takeover speculation. The firm believes the potential takeover by IBM (IBM) has a "lot of merits." HashiCorp is a good strategic asset with strong product capabilities, and deal synergies with a large acquirer such as IBM would be substantial, the analyst tells investors in a research note. Given there is still some uncertainty on a deal being consummated and a typical closing process in the 6-9 month range, BTIG sees limited incremental upside to shares in the near term.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

IBM (IBM) is nearing an acquisition of HashiCorp (HCP) and deal could come together in the coming days, Lauren Thomas and Laura Cooper of Wall Street Journal report, citing people familiar with the matter. A deal for HashiCorp would likely command a premium above where the stock is currently trading, the Journal says. Shares of HashiCorp jumped 7% to $26.37 following the report before halting for volatility. IBM is down 66c to $181.28 in afternoon trade. Reference Link